Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 1

Anidulafungin in the treatment of invasive fungal infections

Authors Kathryn Sabol, Tawanda Gumbo

Published 8 February 2008 Volume 2008:4(1) Pages 71—78

DOI https://doi.org/10.2147/TCRM.S882

Kathryn Sabol, Tawanda Gumbo

University of Texas Southwestern Medical Center, Dallas, TX, USA

Abstract: More antifungal agents have reached clinical use in the past two decades than at any other time. The echinocandins have been a welcome addition to this group, with the latest being anidulafungin. There are several lines of evidence to support anidulafungin’s role as primary therapy for the treatment of invasive candidiasis in non-neutropenic patients, and as alternative therapy to fluconazole in patients with esophageal candidiasis with azole intolerance or triazole-resistant Candida. Pharmacokinetic–pharmacodynamic studies in animals have demonstrated superior efficacy, defined as maximal microbial kill, when compared to fluconazole, regardless of the fluconazole susceptibility of the Candida species. These studies, as well as dose-effect studies in patients, also support the currently recommended dose of anidulafungin. A well designed randomized controlled trial has demonstrated anidulafungin’s efficacy in patients with invasive candidiasis. In this paper, we argue that anidulafungin may be preferable to fluconazole for the treatment of candidemia. However, as of yet, the difference between anidulafungin and the other two licensed echinocandins as first-line therapy for invasive candidiasis is unclear. On the other hand, there is insufficient evidence as of yet to support first-line use of anidulafungin in patients with neutropenia or aspergillosis.

Keywords: anidulafungin, pharmacokinetics-pharmacodynamics, efficacy, candidiasis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

The Danish national type 2 diabetes cohort – the DD2 study

Sørensen HT, Friborg S, Rungby J, Christiansen JS, Vaag A, Beck-Nielsen H

Clinical Epidemiology 2012, 4:1-5

Published Date: 21 September 2012

Genitourinary system trauma after 2003 Bam earthquake in Kerman, Iran

Mohammad Hasan Dehghani Firoozabadi, Mehdi Abedinzadeh, Mohammad Kazem Moslemi

Therapeutics and Clinical Risk Management 2011, 7:49-52

Published Date: 9 February 2011

Review of photodynamic therapy in actinic keratosis and basal cell carcinoma

Marica B Ericson, Ann-Marie Wennberg, Olle Larkö

Therapeutics and Clinical Risk Management 2008, 4:1-9

Published Date: 8 February 2008

Editorial ||FREE PAPER||

Garry M Walsh

Therapeutics and Clinical Risk Management 2008, 4:0-0

Published Date: 8 February 2008

Treating oligohydramnios with extract of Salvia miltiorrhiza: A randomized control trial

Hong-nü Chu, Mei-juan Shen

Therapeutics and Clinical Risk Management 2008, 4:287-290

Published Date: 8 February 2008

Efficacy of Bacillus clausii spores in the prevention of recurrent respiratory infections in children: a pilot study

Gian Luigi Marseglia, Mariangela Tosca, Ignazio Cirillo, Amelia Licari, Maddalena Leone, Alessia Marseglia, Anna Maria Castellazzi, Giorgio Ciprandi

Therapeutics and Clinical Risk Management 2007, 3:13-17

Published Date: 15 March 2007

Etanercept in the treatment of rheumatoid arthritis

Boulos Haraoui, Vivian Bykerk

Therapeutics and Clinical Risk Management 2007, 3:99-105

Published Date: 15 March 2007